Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Roy Schwartz and Harrison Perlstein analyze the state’s new AVOID Act which takes effect April 18 and will require construction attorneys to expedite determining whether or not third parties should be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results